Oppenheimer Initiates Coverage on Quince Therapeutics (NASDAQ:QNCX)

Stock analysts at Oppenheimer began coverage on shares of Quince Therapeutics (NASDAQ:QNCX - Get Free Report) in a research report issued to clients and investors on Monday, Marketbeat.com reports. The brokerage set an "outperform" rating and a $10.00 price target on the stock.

Other research analysts have also issued reports about the stock. Brookline Capital Management initiated coverage on shares of Quince Therapeutics in a research note on Wednesday, December 18th. They set a "buy" rating and a $9.00 price objective on the stock. D. Boral Capital reiterated a "buy" rating and issued a $12.00 price objective on shares of Quince Therapeutics in a report on Wednesday, February 5th. Five research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $8.00.

Quince Therapeutics Stock Down 3.6 %

NASDAQ:QNCX traded down $0.05 during trading hours on Monday, reaching $1.35. 47,716 shares of the stock were exchanged, compared to its average volume of 244,789. The stock has a market cap of $59.40 million, a PE ratio of -1.09 and a beta of 0.71. Quince Therapeutics has a twelve month low of $0.51 and a twelve month high of $2.45. The firm has a 50 day moving average of $1.47 and a 200 day moving average of $1.45. The company has a debt-to-equity ratio of 0.33, a current ratio of 9.53 and a quick ratio of 9.53.

Remove Ads

Quince Therapeutics (NASDAQ:QNCX - Get Free Report) last issued its quarterly earnings results on Monday, March 24th. The company reported ($0.28) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.09). The business had revenue of $0.17 million for the quarter. On average, equities analysts expect that Quince Therapeutics will post -1.21 earnings per share for the current year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the business. Shay Capital LLC raised its stake in shares of Quince Therapeutics by 60.8% during the fourth quarter. Shay Capital LLC now owns 276,799 shares of the company's stock valued at $518,000 after acquiring an additional 104,616 shares during the last quarter. Scharf Investments LLC acquired a new position in Quince Therapeutics during the 4th quarter worth about $170,000. Geode Capital Management LLC grew its position in shares of Quince Therapeutics by 24.2% in the 3rd quarter. Geode Capital Management LLC now owns 339,125 shares of the company's stock valued at $263,000 after buying an additional 66,170 shares during the last quarter. Two Sigma Investments LP acquired a new stake in shares of Quince Therapeutics in the fourth quarter valued at about $57,000. Finally, Virtu Financial LLC acquired a new position in shares of Quince Therapeutics in the fourth quarter worth approximately $55,000. Institutional investors own 30.75% of the company's stock.

Quince Therapeutics Company Profile

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.